Global Biodefense  June 28, 2022 A team of researchers in the US (NIAID, industry) has demonstrated that an inactivated, multivalent whole virus vaccine, delivered intramuscularly or intranasally, is broadly protective against challenges with multiple IAV HA/NA subtypes in both mice and ferrets, including challenges with IAV subtypes not contained in the vaccine. This vaccine approach indicates the feasibility of eliciting broad “universal” IAV protection and identifies a promising candidate for influenza vaccine clinical development…read more. Open Access TECHNICAL ARTICLE